Press Release Archives - CHARM Therapeutics

Press Release

September 10, 2024

CHARM Therapeutics appoints Dr Beverley Carr as Chief Business Officer

PRESS RELEASE CHARM Therapeutics appoints Dr Beverley Carr as Chief Business Officer LONDON – 10…

Content Team

Love2

Press Release

April 30, 2024

CHARM Therapeutics appoints Dr Nicholas Edmunds as Chief Development Officer, Head of Pre-Clinical Development

PRESS RELEASE CHARM Therapeutics appoints Dr Nicholas Edmunds as Chief Development Officer, Head of Pre-Clinical…

Content Team

Love2

Press Release

March 19, 2024

CHARM Therapeutics Announces Foundation of Scientific Advisory Board (SAB)

PRESS RELEASE CHARM Therapeutics Announces Foundation of Scientific Advisory Board (SAB) LONDON, United Kingdom –…

Content Team

Love2

Press Release

December 12, 2023

CHARM Therapeutics Bolsters Leadership Team with Key Promotion and Strategic Appointment

PRESS RELEASE CHARM Therapeutics Bolsters Leadership Team with Key Promotion and Strategic Appointment LONDON, United…

Content Team

Love2

Press Release

May 15, 2023

CHARM Therapeutics Receives Investment for Deep Learning-enabled Drug Discovery Research from NVIDIA

PRESS RELEASE Investment enables CHARM to continue to fund its rapidly growing organization while harnessing…

Content Team

Love2

Press Release

March 20, 2023

CHARM Therapeutics Announces Collaboration with Bristol Myers Squibb to Enable and Accelerate Small Molecule Drug Discovery Programs

PRESS RELEASE Collaboration will leverage CHARM’s DragonFold deep learning platform to identify compounds against targets…

Content Team

Love2

Press Release

January 4, 2023

CHARM Therapeutics Strengthens Leadership Team with Key Appointments to Support Drug Discovery and Development Capability

PRESS RELEASE CHARM Therapeutics Strengthens Leadership Team with Key Appointments to Support Drug Discovery and…

Content Team

Love1

Press Release

June 9, 2022

CHARM Therapeutics launches with a $50 million Series A financing to transform structure-based drug discovery using its proprietary DragonFold AI technology

PRESS RELEASE CHARM Therapeutics is applying its end-to-end 3D deep learning protein-ligand co-folding technology, DragonFold,…

Content Team

Love0

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checkbox-advertisement	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent	1 year	Records the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Functional

Analytics

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.

Cookie	Duration	Description
_ga	2 years	The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_T4NN9DPVGG	2 years	This cookie is installed by Google Analytics.
_gat_gtag_UA_230765459_1	1 minute	Set by Google to distinguish users.
_gid	1 day	Installed by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.

Others

Press Release

CHARM Therapeutics appoints Dr Beverley Carr as Chief Business Officer

CHARM Therapeutics appoints Dr Nicholas Edmunds as Chief Development Officer, Head of Pre-Clinical Development

CHARM Therapeutics Announces Foundation of Scientific Advisory Board (SAB)

CHARM Therapeutics Bolsters Leadership Team with Key Promotion and Strategic Appointment

CHARM Therapeutics Receives Investment for Deep Learning-enabled Drug Discovery Research from NVIDIA

CHARM Therapeutics Announces Collaboration with Bristol Myers Squibb to Enable and Accelerate Small Molecule Drug Discovery Programs

CHARM Therapeutics Strengthens Leadership Team with Key Appointments to Support Drug Discovery and Development Capability

CHARM Therapeutics launches with a $50 million Series A financing to transform structure-based drug discovery using its proprietary DragonFold AI technology

Recent News

Contact